Rajesh Rajpal, MD, chief medical officer, global head of clinical medical affairs, Johnson & Johnson Vision, discusses how greater visual needs are contributing to adverse eye health in younger populations.
With visual needs rising substantially in recent years, eye conditions such as cataract have been shown to be more impactful at an earlier age, said Raj Rajpal, MD, chief medical officer, global head of clinical medical affairs, Johnson & Johnson Vision.
Transcript
Can you speak on the growing prevalence of cataracts in younger populations?
I wouldn't say that they're necessarily being noticed at an earlier age, I think it's just more impactful at an earlier age because of our visual needs. So, certainly all of the types of conditions we've talked about that can contribute to cataracts at an earlier age, we still need to watch for.
Again, whether they're medical causes, trauma, or medications as examples, but because of our greater visual needs, we are finding that we're doing cataract surgery at an earlier age because patients’ vision is impacting their life and that's when we primarily choose to perform cataract surgery.
It’s when a patient's vision is impacting their daily functioning, and therefore then we can, by cataract surgery, remove the natural lens, the cloudy lens of the eye, and implant an intraocular lens that makes up for the power. And then we have different options in how we select those intraocular lenses and what we do in cataract surgery.
Disparities in Telehealth Access Undermine Adoption Among Patients With Schizophrenia
January 16th 2025The COVID-19 pandemic accelerated the widespread adoption of telemental health care, and new research indicates significant racial and ethnic disparities in access to this technology among Medicaid beneficiaries with schizophrenia.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen